Mindmed presents phase 2b study of mm120 for generalized anxiety disorder (gad) at american psychiatric association (apa) annual meeting in new york

New york--(business wire)---- $mnmd--mind medicine (mindmed) inc. (nasdaq: mnmd) (the “company” or “mindmed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented data from mmed008, its phase 2b study of mm120 (lysergide d-tartrate) in the treatment of gad in adults. mm120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints. the study was presen.
MNMD Ratings Summary
MNMD Quant Ranking